CUBE vs RXRX · P/E 25, rev $1.07B vs rev $58.8M
CubeSmart (CUBE) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the CUBE and RXRX stock pages for the full models.
Not investment advice.